leadf
logo-loader
viewANGLE PLC

ANGLE chief sees Parsotix sales “turbocharged” by Manchester Uni deal

ANGLE PLC (LON:AGL) has signed a contract with the University of Manchester through Cancer Research UK that will see its breakthrough liquid biopsy system Parsortix used in research trials.

Andrew Newland, chief executive, tells Proactive Investors: “This is really important. It comes after four years of working to develop the tests and on the strength of that data they [the University of Manchester] now want to incorporate it for routine use in their clinical laboratory.”

He says Parsortix is already being used in 10 clinical trials, and that the deal is with “one of the foremost customers that we could possibly hope for,” adding that this should give the rest of the market confidence, and “turbocharge” its sales in research use.

Quick facts: ANGLE PLC

Price: 61.7 GBX

AIM:AGL
Market: AIM
Market Cap: £132.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ANGLE completes FDA submission for Parsortix system for metastatic breast cancer

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC). Newland calls the announcement 'a massive day' after...

on 28/9/20

2 min read